The only PI3K inhibitor approved for the treatment of non-hematopoietic cancers in adults is alpelisib, which shows relative specificity for PI3Kα and which is approved for a subset of advanced or metastatic breast cancer patients with PIK3CA mutations whose disease has progressed on or after an endocrine-based regimen (Narayan et al., 2020). This evidence concerns the gene PIK3CA and hematopoietic and lymphoid cell neoplasm.